{"id":"bdl-regimen","safety":{"commonSideEffects":[{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"QT prolongation"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BDL typically refers to a regimen combining Bedaquiline, Delamanid, and Linezolid, which are used together to treat drug-resistant tuberculosis. These agents work through different mechanisms: bedaquiline inhibits mycobacterial ATP synthase, delamanid is a prodrug that generates reactive nitrogen species, and linezolid inhibits bacterial protein synthesis. The combination approach is designed to overcome resistance mechanisms and improve treatment outcomes in difficult-to-treat TB cases.","oneSentence":"BDL is a combination chemotherapy regimen used to treat tuberculosis by combining multiple anti-tuberculous agents.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:41:21.875Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Drug-resistant tuberculosis (MDR-TB and XDR-TB)"}]},"trialDetails":[{"nctId":"NCT06114628","phase":"PHASE2","title":"Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-01-09","conditions":"Pulmonary Tuberculosis","enrollment":2500},{"nctId":"NCT06476210","phase":"PHASE4","title":"The Safety and Efficacy of BDL(Bedaquiline Plus Delamanid Plus Linezolid) Regimen in Subjects With Pulmonary Infection of Multi-drug Resistant Tuberculosis (MDR-TB) or Rifampicin-Resistant Tuberculosis (RR-TB)","status":"RECRUITING","sponsor":"Beijing Chest Hospital","startDate":"2024-06","conditions":"Pulmonary Tuberculosis","enrollment":45}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"BDL regimen","genericName":"BDL regimen","companyName":"Beijing Chest Hospital","companyId":"beijing-chest-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BDL is a combination chemotherapy regimen used to treat tuberculosis by combining multiple anti-tuberculous agents. Used for Drug-resistant tuberculosis (MDR-TB and XDR-TB).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}